Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI105873

Enzymic properties of different types of human erythrocyte glucose-6-phosphate dehydrogenase, with characterization of two new genetic variants

L. Luzzatto and A. Afolayan

Sub-Department of Haematology, University of Ibadan, Ibadan, Nigeria

Find articles by Luzzatto, L. in: PubMed | Google Scholar

Sub-Department of Haematology, University of Ibadan, Ibadan, Nigeria

Find articles by Afolayan, A. in: PubMed | Google Scholar

Published August 1, 1968 - More info

Published in Volume 47, Issue 8 on August 1, 1968
J Clin Invest. 1968;47(8):1833–1842. https://doi.org/10.1172/JCI105873.
© 1968 The American Society for Clinical Investigation
Published August 1, 1968 - Version history
View PDF
Abstract

Enzymic properties have been compared in the following five genetic variants of glucose-6-phosphate dehydrogenase from human erythrocytes: the two common variants with normal activity, A and B; the common variant associated with enzyme deficiency, A-; and two new rare variants, “Ijebu-Ode” and “Ita-Bale.”

The maximal velocity of the enzyme reaction (Vmax) increases steadily with pH over the entire range explored (from pH 5.5 to 9.5) for all enzyme variants when buffers are used that show no specific ion effects on enzyme activity. Small differences are found among the variants in the pH range 7.5-8.2, where A and B show a “peak and trough,” while A-, “Ijebu-Ode,” and “Ita-Bale” exhibit a plateau.

When the effects of reagents that bind to sulphydryl groups are compared, iodoacetate, bromoacetate, and iodoacetamide are weak inhibitors, while N-ethylmaleimide (NEM) and hydroxymercuribenzoate (HMB) are potent inhibitors. The last two reagents have differential inhibitory action on different variants; one of these, “Ijebu-Ode,” is strikingly resistant to HMB and totally resistant to NEM (up to 3 mmoles/liter).

The enzyme inactivation as a function of temperature exhibits distinctive profiles for all variants examined.

Both of the new variants described differ significantly from the normal B type in several respects: “Ijebu-Ode” in electrophoretic mobility, thermostability, dependence of Vmax on pH, and resistance to sulphydryl group reagents; “Ita-Bale” in electrophoretic mobility, Michaelis constant (Km) for glucose-6-phosphate, and dependence of Vmax on pH. When these data are compared with those available in the literature, both variants are different from all those previously described. The estimated frequencies of the corresponding genes in western Nigeria are between 0.0005 and 0.0025 for “Ijebu-Ode” and less than 0.0005 for “Ita-Bale”.

The A- variant, compared to A, has a distinctly higher Km for 2-deoxyglucose-6-phosphate and is more inhibited by very low concentrations of HMB. These are the first observed differences in kinetic properties between A and A-.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1833
page 1833
icon of scanned page 1834
page 1834
icon of scanned page 1835
page 1835
icon of scanned page 1836
page 1836
icon of scanned page 1837
page 1837
icon of scanned page 1838
page 1838
icon of scanned page 1839
page 1839
icon of scanned page 1840
page 1840
icon of scanned page 1841
page 1841
icon of scanned page 1842
page 1842
Version history
  • Version 1 (August 1, 1968): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts